Open AccessIntroducing new and repurposed TB drugs: the endTB experience
Author(s) -
Kwonjune J. Seung,
Uzma Khan,
Francis Varaine,
Saba Ahmed,
Mathieu Bastard,
S. Cloez,
Dagim Damtew,
Molly F Franke,
Krzysztof Herboczek,
Helena Huerga,
Shirajul Islam,
Hayk Karakozian,
Naira Khachatryan,
J Kliesckova,
Asif Khan,
Muhammad Umair Khan,
Palwasha Khan,
Tinatin Kotrikadze,
Nathalie Lachenal,
Leonid Lecca,
Putri Lenggogeni,
S Maretbayeva,
Nara Melikyan,
Anita Mesić,
Carole D. Mitnick,
Malefetsane A. Mofolo,
Christophe Perrin,
Michele Richard,
Yoseph Tassew,
Alex Telnov,
Stalz Charles Vilbrun,
Simuyu G Wanjala,
Michael Rich,
Cathy Hewison
Publication year - 2020
Publication title -
the international journal of tuberculosis and lung disease/the international journal of tuberculosis and lung disease. articles traduits en français ...
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.103
H-Index - 110
eISSN - 1815-7920
pISSN - 1027-3719
DOI - 10.5588/ijtld.20.0141
Subject(s) - medicine , pharmacovigilance , pace , scale (ratio) , risk analysis (engineering) , intensive care medicine , drug , pharmacology , physics , geodesy , quantum mechanics , geography
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major implementation challenges encountered in 17 endTB countries. We provide insights on how national TB programmes and other stakeholders can scale-up the programmatic use of new and repurposed TB drugs, while building scientific evidence about their safety and efficacy. For any new drug or diagnostic, multiple market barriers can slow the pace of scale-up. During 2015–2019, endTB was successful in increasing the number of patients receiving new and repurposed TB drugs in 17 countries. The endTB experience has many lessons, which are relevant to country level introduction of new TB drugs, as well as non-TB drugs and diagnostics. For example: the importation of TB drugs is possible even in the absence of registration; emphasis on good clinical monitoring is more important than pharmacovigilance reporting; national guidelines and expert committees can both facilitate and hinder innovative practice; clinicians use new and repurposed TB drugs when they are available; data collection to generate scientific evidence requires financial and human resources; pilot projects can drive national scale-up.